Minutes - Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - 20 November 2025
EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 November 2025, 13:30 (CET) to 14 November 2025, 17:30 (CET)
List of European Union reference dates (EURD) and frequency of submission of periodic safety update reports (PSURs)
Call for user acceptance testers for the read functionality in the Public Product Management Service (PMS) Application Programming Interface (API)
Shortage Prevention Plan (SPP) and Shortage Mitigation Plan (SMP) pilot report
Concept Paper on the revision of Annex 3 of the guidelines on Good Manufacturing Practice for Radiopharmaceuticals
Quarterly System Demo - Q4 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 16 December 2025, 09:30 (CET) to 16 December 2025, 12:35 (CET)
Overview of (invented) names reviewed in November 2025 by the Name Review Group (NRG) adopted at the CHMP meeting of 11 December 2025
Human medicines European public assessment report (EPAR): Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals), pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted), Date of authorisation: 10/10/2009, Revision: 12, Status: Authorised
EMA/PE/0000182345